Download SYDNEY CANCER CONFERENCE 2014 PROGRAM  WEDNESDAY 26 NOVEMBER 2014  THURSDAY 27 NOVEMBER 2014 

SYDNEY CANCER CONFERENCE 2014 PROGRAM WEDNESDAY 26 NOVEMBER 2014 1800 ‐ 1900 1900 ‐ 2000 New Law Building LT 101 Public lecture: Chairs – A/Prof Glen Reid & Dr Sonia Yip New ways to fight cancer: stirring our defences against infection into action
Prof Ian Frazer, Translational Research Institute, Brisbane, Australia Refreshments THURSDAY 27 NOVEMBER 2014 Session 1 Plenary: Chair ‐ Prof Graham Mann 0900 ‐ 0920 0920 ‐ 1030 Welcome and conference opening Prof Graham Mann and Hon Jillian Skinner, MP KN01 Prof Sir David Lane Ludwig Institute for Cancer Research and A*STAR New insights into p53 pathways function 1030 ‐ 1100 Morning tea and poster viewing Biomarkers ‐ prognostic, predictive and disease monitoring roles Chair: A/Prof Alexander Engel New Law LT 104 S1 1100
Prof Stephen Clarke Sydney Vital and Royal North Shore Hospital Inflammation in cancer Targeted therapies ‐ new targets, new drugs
Chair: Dr Andrew Katsifis New Law LT 106 S6
Prof Grant McArthur Peter MacCallum Cancer Centre Oncogenic targets in melanoma: we are not done yet 1100
1130 S2 Dr Jeanne Tie The Walter And Eliza Hall Institute of Medical Research Potential Clinical Applications of Circulating Tumour DNA (ctDNA) in colorectal cancer 1130
S7
Prof Sandra O’Toole Garvan Institute of Medical Research Challenges and opportunities of using new technologies in cancer mutation testing 1130
1200 S3 A/Prof Mark Molloy Macquarie University Wherefore art thou Biomarker(s)? : Opportunities for proteomics S4 Dr Andy Chin‐Meng Chang Children's Medical Research Institute STC1 expression is associated with tumour growth and metastasis in breast cancer 1200
S8
A/Prof Georgina Long Melanoma Institute Australia and The University of Sydney Targeted Therapies: New Targets, New Drugs 1200
1220
S9
1220
Dr Mariana Brocardo Westmead Millennium Institute Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5‐fluorouracil chemotherapy 1240
S10
1240
Dr Janet Martin Kolling Institute of Medical Research A new targeted therapy for the treatment of triple‐negative breast cancer 1100 1220 1240 New Law Building LT 101 New Law Building Foyer Session 2A Session 2B S5 Ms Joyce Lee Children's Medical Research Institute The C‐Circle Assay as a blood test for ALT cancer activity Session 2C Implementation research in cancer (1)
Chair: A/Prof Tim Shaw New Law Seminar Room 100 S11
Prof John Hopper School of Population and Global Health, The University of Melbourne Using genomics to make a difference ‐ can clinical and population health practice be changed so that things can be “done better”? S12
Prof Kate White The University of Sydney Integration of supportive care and clinical research – overcoming barriers to implementation S13
Prof Simon Chapman The University of Sydney Removing the cancer emperor's clothes: how research moved into practice with plain tobacco packaging S14
A/Prof Freddy Sitas Cancer Council NSW Smoking cessation after cancer S15
A/Prof Claire Vajdic University of New South Wales Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population‐based nested case‐control study 1300 ‐ 1410 1330 ‐ 1410 Lunch and poster viewing New Law Building Foyer 1) Career hints for postgraduates LT 104 2) Talking to commercial partners ‐ when and how? Chair – Prof Grant McArthur Presenters – Dr Jennifer MacDiarmid and Dr Andrew Tindell LT 106 Lunchtime workshops Session 3 Plenary: Chair – A/Prof Glen Reid 1410 KN02 Prof Fiona Watt King's College London Intercellular communication in epidermal carcinogenesis New Law Building LT 101 1455 Gai Grayson, consumer 1510 Afternoon tea Session 4A Session 4B Experimental therapies & discovery (1) Chair: Prof Stephen Clarke New Law LT 104 Tumour immunology
Chair: Dr Kellie Charles New Law LT 106 Quality of life, patient reported outcomes & survivorship issues Chair: Prof Martin Stockler New Law Seminar Room 100 1530 S16 1530
Dr Jennifer MacDiarmid EnGeneIC LTD Targeted EDVTMnanocells as versatile vectors for delivery of therapeutics in cancer : Translating a platform technology into human clinical trials 1530
S21
Prof Derek Hart ANZAC Research Institute Applications of monoclonal antibodies to dendritic cells for the diagnosis and treatment of haematological and other malignancies
S26
Prof Madeleine King The University of Sydney Deriving cancer‐specific utility weights from the QLQ‐C30: a discrete choice methods experiment 1600 S17 Prof Rebecca S Mason The University of Sydney Photoprotection by vitamin D compounds 1600
S22
Prof John Rasko Royal Prince Alfred Hospital Cell and gene therapy update 1600
S27
Prof Frances Boyle Mater Hospital and University of Sydney Australian implementation of scalp cooling for prevention of chemotherapy induced alopecia 1630 S18 Dr Alexander Swarbrick Garvan Institute of Medical Research ID4 controls mammary stem cells and marks breast cancers with a stem cell like phenotype 1630
S23
Dr Catriona McNeil Chris O’Brien Lifehouse, Royal Prince Alfred Hospital Cancer immunotherapy – Holy Grail or Pandora’s Box 1630
S28
A/Prof Janette Vardy The University of Sydney Cognitive function in cancer survivors 1650 S19 Dr Konstantin Horas ANZAC Research Institute Loss of vitamin D receptor in breast cancer cells enhances bone metastasis in a murine model of breast cancer 1650
S24
Dr Chris Weir Bill Walsh Translational Cancer Research Laboratory A safety study treating canine cancer patients with autologous vaccines 1650
S29
Ms Rebekah Laidsaar‐Powell CeMPED, The University of Sydney A new conceptual framework and clinical strategies to manage and enhance family involvement in cancer consultations 1710 S20 Ms Mingqi Han Children's Medical Research Institute Can ATRX deficiency be exploited for anti‐cancer therapy? 1710
1710
S25
Dr David Gallego Ortega Garvan Institute of Medical Research The ETS transcription factor ELF5 is a key determinant of the lethal phenotype in luminal breast cancer, driving the acquisition of antiestrogen resistance and metastatic activity 1730 POSTER VIEWING SESSION AND CONFERENCE COCKTAIL FUNCTION
New Law Building Foyer Session 4C S30
Ms Brooke Nickel Screening & Test Evaluation Program, School of Public Health, The University of Sydney What's in a name: how different terminology impacts community concern and treatment preferences for DCIS New Law Building Foyer FRIDAY 28 NOVEMBER 2014 New Law Building LT 101 Session 5 Plenary: Chair ‐ Prof Jane Young 900 KN03 Prof Eva Grunfeld Ontario Institute for Cancer Research and Department of Family and Community Medicine, University of Toronto Evaluating access and quality across the cancer care continuum S31 Prof Sallie‐Anne Pearson The University of Sydney Big data linkages: The magic bullet for cancer health service research? Morning Tea 945 1010 New Law Building Foyer Session 6A Session 6B Experimental therapies & discovery (2) Developing novel drugs for new targets Chair: A/Prof Glen Reid Chair: Dr Sonia Yip New Law LT 104 New Law LT 106 Session 6C Implementation research in cancer (2) Chair: Dr Nicole Rankin New Law Seminar Room 100 1030 S32 1030
Prof Susan Clark Garvan Institute of Medical Research Whole genome methylation sequencing identifies potential epigenetic‐based cancer biomarkers S37
Prof Kenneth O'Byrne The University of Queensland Non‐mutated proteins as targets for cancer therapy 1030
S42
Prof Afaf Girgis Ingham Institute for Applied Medical Research, UNSW The PROMPT‐Care Project: eHealth system utilising patient reported outcomes to inform personalised cancer treatment and care 1100 S33 1100
Prof Maria Kavallaris Children's Cancer Institute Microtubule targets in cancer: potential of nanotechnology‐
based therapeutics S38
Prof John Simes NHMRC Clinical Trials Centre, The University of Sydney; Sydney Catalyst Determining the effectiveness of targeted therapies: challenges, strategies and pitfalls 1100
S43
A/Prof Tim Shaw The University of Sydney A systematic approach to closing evidence gaps in cancer care 1130 S34 1130
A/Prof Guy Lyons The University of Sydney Cancer progression and recurrence: what we can learn from evolutionary biology S39
1130
A/Prof Clare Scott Walter and Eliza Hall Institute of Medical Research Using patient‐derived xenografts to define actionable aberrations in high‐grade serous cancer S44
Ms Geraldine Largey Southern Melbourne Integrated Cancer Service Lung cancer referral interval times: A mixed methods study 1150 S35 Dr Angelica Merlot The University of Sydney Exploiting hsa to stimulate the delivery and anti‐tumour activity of the anti‐cancer thiosemicarbazone, Dp44mT, to cancer cells S40
1150
Dr Anthony Glover Kolling Institute of Medical Research Restoring expression of miR‐7 by targeted bacterial minicells inhibits the MAPK/ERK pathway and offers a novel therapy for adrenocortical cancer S45
Ms Kate McBride Westmead Institute for Cancer Research An international survey of awareness of genetic risk in the clinical sarcoma community 1210 S36 1210
Dr Sumit Sahni The University of Sydney Metastasis suppressor, N‐MYC downstream regulated gene 1 (NDRG1), suppresses pro‐survival autophagic pathway in cancer cells S41
Ms Marissa Williams Asbestos Diseases Research Institute Tumour suppressor functions of miR‐192 and miR‐193a‐3p in malignant pleural mesothelioma S46
Dr Tracy Robinson The University of Sydney Using a multi‐ disciplinary program of cancer care as a vehicle for more effective research translation 1230 Lunch and poster viewing Session 7 Plenary: Chair – Dr Sonia Yip 1330 KN04 Prof Dennis Lo The Chinese University of Hong Kong Plasma DNA‐based genomic and methylomic profiling in cancer and prenatal diagnosis: two sides of the same coin 1150
1210
New Law Building Foyer New Law Building LT 101 Session 8A Session 8B Advances in technologies for patient treatment Cancer genomics & pathways Chair: Prof Ross Smith Chair: Dr Beata Ujvari New Law LT 104 New Law LT 106 Session 8C Public health and translational research Chair: Prof Glenn Salkeld New Law Seminar Room 100 1415 S47 Prof Dietmar Hutmacher Queensland University of Technology Tissue engineered humanized bone supports human hematopoiesis in vivo 1415
S52
A/Prof Andrew Barbour Translational Research Institute Oesophageal adenocarcinoma genomics 1415
S57
A/Prof Penelope Webb QIMR Berghofer Medical Research Institute Translating epidemiological research in gynaecological cancer into cancer control 1445 S48 Prof Andrew Scott Ludwig Institute for Cancer Research Novel antibody scaffolds for therapy of solid tumours 1445
S53
Prof Anna De Fazio Sydney‐West Translational Cancer Research Centre and The University of Sydney Know thy enemy: using genomics to understand molecular sub‐
types of epithelial ovarian cancer 1445
S58
Prof Jane Young The University of Sydney Survivorship care for people with colorectal cancer: a population‐
based survey of patients' experiences and preferences 1515 S49 Dr Aiqun Xue Kolling Institute for Medical Research Applications of patient‐derived subrenal capsule tumour xenograft models in mice 1515
S54
Prof Helen Rizos Macquarie University Targeted therapy resistance and implications for personalised therapy in melanoma 1515
S59
Dr Anne Cust The University of Sydney Impact of common genomic variants on melanoma risk prediction 1535 S50 A/Prof Yves De Deene Macquarie University Quantitative biologically guided cancer treatment using multi‐nuclear magnetic resonance imaging 1535
S55
A/Prof Maija Kohonen‐Corish Garvan Institute of Medical Research A new beta‐catenin regulatory pathway as a potential treatment target in colon cancer 1535
S60
Ms Jolyn Hersch School of Public Health, The University of Sydney Informing women about overdetection of breast cancer: randomised trial of a mammography screening decision aid 1555 S51 1555
Dr Roger Bourne The University of Sydney Distinctive water diffusion properties of epithelia may be the key to better cancer imaging techniques S56
Dr Emily Colvin Kolling Institute of Medical Research Potential Driver Genes of Ovarian Carcinogenesis identified by Sleeping Beauty Mutagenesis 1555
S61
Ms Qingwei Luo Cancer Council NSW Why are two in five prostate cancer cases recorded as having “unknown” stage of disease in an Australian popula on‐based cancer registry? A study of health service factors 1615 Afternoon tea New Law Building Foyer Session 9 New Law Building LT 101 1635 PANEL DISCUSSION Chair: Adam Spencer International participants: Prof Sir David Lane, Prof Eva Grunfeld, Prof Dennis Lo National participants: A/Prof Alexander Engel, A/Prof Lisa Horvath, A/Prof Clare Scott Awards Presentation and Closing Remarks 1720